Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Public Citizen Re-Petitions FDA To Withdraw Obesity Drug Meridia

Executive Summary

Public Citizen has renewed its call for FDA to ban Abbott's obesity drug Meridia (sibutramine) following the release of preliminary results of a 10,000 patient study that showed the drug had a slightly higher rate of cardiovascular events

You may also be interested in...



Weighing Obesity Risk: FDA, EMEA Use Different Scales For Abbott's Meridia

Abbott is withdrawing its anti-obesity drug sibutramine from the European Union markets at the urging of the European Medicines Agency

Weighing Obesity Risk: FDA, EMEA Use Different Scales For Abbott's Meridia

Abbott is withdrawing its anti-obesity drug sibutramine from the European Union markets at the urging of the European Medicines Agency

Will A CV Warning On Meridia Alter FDA Views On Obesity Drugs?

The FDA's cardiovascular safety warning on Abbott's obesity drug Meridia (sibutramine) - which was issued in light of early results from a 10,000 patient strong outcomes study - could mean higher regulatory risk for up-and-coming obesity drugs

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051745

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel